
By Michael A. Carrier & Gwendolyn J.Lindsay Cooley, Rutgers Law School & Wisconsin Department of Justice
Consider a merger of two firms in the pharmaceutical industry. Each has previously engaged in antitrust violations. In considering whether to allow the merger, how much weight should the antitrust agencies give to these prior bad acts? How important should this evidence be to courts? These critical questions have not received sufficient attention.
In the 2010 Horizontal Merger Guidelines, the federal antitrust agencies address collusion, one of the two main types of anticompetitive behavior underlying merger challenges. We support the Guidelines’ attention on this conduct. And we believe that merger enforcement can be improved in this area because the agencies have not been consistent in recognizing prior collusion.
The second main type of prior conduct, unilateral behavior, presents even more uncertainty as the Guidelines do not address it. We offer a framework that suggests considering prior bad acts when (1) the markets are similar, (2) there is a connection between the conduct and the markets covered by the merger, and (3) there is sufficient proof of the prior bad acts.
We supplement our discussion of collusive and unilateral behavior by offering case studies involving mergers for which there was strong evidence that the companies had previously engaged in this conduct. And we conclude by explaining why, in mergers in which prior bad acts counsel agency action, the array of potential relief should include not just a lawsuit to block the merger but also behavioral remedies.
Featured News
Live Nation Under Criminal Antitrust Investigation Over Pandemic-Era Refund Policies
May 19, 2025 by
CPI
BCLP Strengthens Healthcare and Antitrust Litigation Practice
May 19, 2025 by
CPI
Italy Fines AI Chatbot Maker Replika €5 Million Over Privacy Violations
May 19, 2025 by
CPI
Germany’s Antitrust Chief: EU-US Tech Policy Divide Is Mostly Rhetoric
May 19, 2025 by
CPI
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas